In fact, high eIF5B levels were associated with poor prognosis for HCC patients, while low eIF5B levels resulted in smaller tumor sizes, lower vascular invasions, and better survival rates (Wang et al., 2016). This evidence concerns the gene EIF5B and hepatocellular carcinoma.